Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Condition:   Lymphoma, Large B-Cell, Diffuse Intervention:   Biological: Nonconforming Lisocabtagene Maraleucel Sponsor:   Juno Therapeutics, a Subsidiary of Celgene Temporarily not available

Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials